SCHEMBL13656202

SCHEMBL13656202

COOSNc1ccc(OCC(=O)NCCNc2ccc(F)c(F)c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 2/20 0.49
GRIN2B Q13224 2/20 0.49
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
HTT P42858 2/20 0.41
PPARG P37231 1/20 0.41
NCOA2 Q15596 1/20 0.41
NCOA1 Q15788 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
NR2E3 Q9Y5X4 1/20 0.41
NCOR2 Q9Y618 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
HPGD P15428 3/20 0.40
CYP1A2 P05177 2/20 0.40
ALDH1A1 P00352 2/20 0.40
FFAR1 O14842 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
CYP2D6 P10635 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13656111 0.86 GRIN1 (0.67) GRIN1GRIN2BMEN1KMT2AHTT
SCHEMBL8007245 0.83 MEN1 (0.53) GRIN1GRIN2BMEN1KMT2AHTT
SCHEMBL2019165 0.80 GRIN1 (0.74) GRIN1GRIN2BMEN1KMT2AHTT
SCHEMBL4187617 0.78 GRIN1 (0.48) GRIN1GRIN2BMEN1KMT2AHTT
SCHEMBL13656132 0.75 GRIN1 (0.67) GRIN1GRIN2BHPGDCYP1A2ALDH1A1
SCHEMBL13656207 0.73 GRIN1 (0.69) GRIN1GRIN2BHTTALDH1A1PTPN1
SCHEMBL13656203 0.73 GRIN1 (0.71) GRIN1GRIN2BMEN1KMT2AHTT
SCHEMBL13656236 0.72 MAPT (0.53) GRIN1GRIN2BMEN1KMT2AHTT
SCHEMBL4255057 0.71 GRIN1 (0.42) GRIN1GRIN2BMEN1KMT2AHTT
SCHEMBL8092883 0.71 MAOB (0.47) GRIN1GRIN2BMEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420680-B2 NMDA receptor antagonists for neuroprotection EMORY UNIVERSITY (US) 2013-04-16 US disclosed
US-20090253710-A1 NMDA Receptor Antagonists for Neuroprotection EMORY UNIVERSITY 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253710-A1 NMDA Receptor Antagonists for Neuroprotection GRIN1, GRIN2C, GRIK1 GRIN1 1/4885GRIN2B 7/4885MEN1 3672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.